“…MO sequences and dosages used were: irx3b 5'-ATAGCCTAGCTGCGGGAGAGACATG-3', 1 ng (Wingert and Davidson, 2011); ptger2a MO1 5'-GATGTTGGCATGTTTGAGAGCATGC-3', 3 ng (North et al, 2007); ptger2a MO2 5'-ACTGTCAATACAGGTCCCATTTTC-3', 1.6 ng (North et al, 2007); ptger2a MO3 splice 5'-CAATAAATCTTACTATTAACGGCAG-3', 3 ng; ptger2a MO4 splice 5'-ATGTACACACGGATCTG-AAGAGAAG-3', 3 ng; ptger4a MO1 5'-CGCGCTGGAGGTCTGGAG-ATCGCGC-3', 3 ng (North et al, 2007); ptger4a MO2 5'-CACGGTGGGCTCCATGCTGCTGCTG-3', 3 ng (Cha et al, 2006); ptger4a MO3 splice 5'-CCTGGAACTTACAACAAGCGGGATT-3', 3 ng; ptger4a MO4 splice 5'-TGAGAAACA-CCTGGACCTGCCAGAA-3', 3 ng; ptgs1 MO 5'-TCAGCAAAAAGTTACACTCTCTCAT-3’, 3 ng (North et al, 2007); ptgs2a MO 5'-AACCAGTTTATTCATTCCAGAAGTG-3', 3 ng (Grosser et al, 2002); ptgs1 MO splice 5'-AACTTTCATTGCTC-ACCTCTCATTG-3', 2 ng; ptgs2a MO splice 5'-ATTCAACTTA-CACAACAGGATATAG-3', 2 ng (Yeh et al, 2009), sim1a MO 5'-TCGACTTCTCCTTCATGCTCTACGG-3', 1 ng (Cheng and Wingert, 2015). To assess knockdown efficacy, RT-PCR and sequence analysis was performed as previously described (Marra and Wingert, 2016) and using the following primers, where uppercase letters indicate location in an exon and lowercase indicates primer location in an intron: ptgs1-F1 5'-TTTATTTATTTGCAGCTTTTTCTT-3'; ptgs1-R1 5'-CAGTGTTTGATGAAGTCGGGCTTTC-3'; ptgs2a-F1 5'-CTGAGCTTCTCACACGCATCAAAT-3'; ptgs2a-R1 5'-GGCGAAGAAAGCAAACATGAGACT-3'; ptger2a-F1 5'-AGACCGAGCGTATGCCAATGT- 3'; ptger2a-R4 5'-caggagggctaataattcagactt-3'; ptger2a-F3 5'-ctgtttcagtgatcagtttgt-3'; ptger2a-R7 5'-CCGCAGAGCTATGAGATCAGTC-3'; ptger2a-R8 5'-GCTGAGGATGATGAACACCAAG-3'; ptger4a-F3 5'-ATGGTCATCCTGTTGATCGCC-3'; ptger4a-R2 5'-aatgagagtcctggaacttac-3'; ptger4a-F5 5'-gggtgtagtcatttatgttgagca-3'; ptger4a-R5 5'-CAGGACCGCTTTACGCAGTAAG-3'.…”